leadf
logo-loader
viewTonix Pharmaceuticals

Tonix Pharmaceuticals forms second research collaboration with Massachusetts General Hospital

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has signed a second research collaboration agreement with Massachusetts General Hospital.

Dr Lederman says while the first collaboration is centered on heart transplantation, the second focuses on developing its antibody TNX-1500 to prevent and treat kidney transplant rejection.

Quick facts: Tonix Pharmaceuticals

Price: 0.91 USD

NASDAQ:TNXP
Market: NASDAQ
Market Cap: $240.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tonix Pharmaceuticals named herein, including the promotion by the Company of Tonix Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Tonix Pharmaceuticals reports positive Phase 3 findings in its RELIEF study...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman tells Proactive the New York-based clinical-stage biopharmaceutical company is 'delighted' as it recently reported positive findings in its Phase 3 RELIEF study to treat fibromyalgia. Dr Lederman says now, the firm will...

on 12/15/2020

2 min read